C Diff Diagnosis

The global Clostridium Diagnostics Market is anticipated to grow at a 12.2% CAGR from 2022 to 2032, from US$ 2.5 billion to US$ 7.8 billion. The market saw a 13.6% CAGR between 2015 and 2021. The market is expanding as a result of increased awareness-raising activities for clostridium-related illnesses and their rising prevalence. There has been an increased focus of players in […]

A testing strategy of PCR plus toxin EIA helped predict recurrent CDI.

A testing strategy of PCR plus toxin EIA helped predict recurrent CDI.

A-two-step-algorithm-for-Clostridioides-difficile-infection-testing-may-improve-detection-and-reduce-unnecessary-treatment

MicroRNA has shown the potential to more effectively and accurately identify C. difficile infections and manage it after diagnosis.

Misclassification of Clostridioides difficile colonization as hospital-onset C. difficile infection (HO-CDI) can lead to unnecessary treatment of patients and substantial financial penalties for hospitals. We successfully implemented mandatory C. difficile PCR testing approval a …

Clostridioides difficile infection can be difficult to treat, but increasing disease awareness can improve screening and treatment outcomes.

ORLANDO — A hospital reduced the rate of hospital-onset cases of Clostridioides difficile infection with a standardized system for early recognition and testing, researchers found.

The reported C difficile healthcare-acquired infections rates per 10,000 patient days did not significantly change. The rates were 8.07 in the 6-month preintervention period and 8.77 in the intervention period for facilities A and B combined.

CT value was an acceptable predictor for EIA toxin but less so for clinical severity. Our study potentially supports a diagnostic algorithm including CT value to reduce the number of EIA toxin assays performed.

CT value was an acceptable predictor for EIA toxin but less so for clinical severity. Our study potentially supports a diagnostic algorithm including CT value to reduce the number of EIA toxin assays performed.

There are no established standards for the diagnosis of Clostridioides difficile infection (CDI), even though the importance of this infection in humans is well known. The effectiveness of the commercially available techniques, which are all standardized for use with human feces, is also limi …

Clostridioides difficile (formerly called Clostridium difficile, C. difficile) infection (CDI) is listed as an urgent threat on the 2019 antibiotic resistance threats report in the United States by the Centers for Disease Control and Prevention. Early detection and appropriate d …

Clostridioides difficile (formerly called Clostridium difficile, C. difficile) infection (CDI) is listed as an urgent threat on the 2019 antibiotic resistance threats report in the United States by the Centers for Disease Control and Prevention. Early detection and appropriate d …

Clostridioides difficile is one of the leading pathogens causing nosocomial infection. The infection can range from mild to severe, and rapid identification is pivotal for early clinical diagnosis and appropriate treatment. Here, a genetic testing platform for toxins, referred to as OC-MAB (orthogon …

Clostridioides difficile is one of the leading pathogens causing nosocomial infection. The infection can range from mild to severe, and rapid identification is pivotal for early clinical diagnosis and appropriate treatment. Here, a genetic testing platform for toxins, referred to as OC-MAB (orthogon …

The PathFlow C. difficile GDH & Tox A/B Combi Cassette simultaneously detects three distinct antigens in faecal specimens for C. difficile; GDH, Toxin A and Toxin B.

Two-step Clostridioides difficile testing was associated with decreased reported incidence of hospital-onset C. difficile infection and C. difficile-specific antibiotic use, researchers found.

The global Clostridium Diagnostics Market revenue is projected to secure US$ 7.8 Billion by 2032 while recording a CAGR of 12.2% during the forecast period. The growth of the market can be attributed to the growing prevalence of clostridium-related diseases and the growing awareness campaigns lau...

There is limited utility of bedside clinical examination alone in detecting C. difficile infection. Accurate diagnosis of C. difficile infection requires thoughtful clinical assessment for interpretation of microbiologic testing in all suspected cases.

The 24-hour autocancellation of uncollected C. difficile orders reduced testing but did not result in reported HAI reduction.

A study of hospitalized patients with diarrhea found that collecting stool samples and testing all of them identified almost 30% more cases of C. diff than the standard of care.

A study of hospitalized patients with diarrhea found that collecting stool samples and testing all of them identified almost 30% more cases of C. diff than the standard of care.

A multi-disciplinary approach led to improved diagnostic stewardship to identify true CDI cases. This in turn, reduced the number of reported HO-CDIs, and resulted in potentially more than $1,080,000 in patient care savings.

Two-step testing is associated with decreased reported incidence of HO-CDI, likely by improving diagnostic specificity. The parallel decrease in C. difficile specific antibiotic use offers indirect reassurance against under-diagnosis of C. difficile infections still requiring treatment by clinician …

Two-step testing is associated with decreased reported incidence of HO-CDI, likely by improving diagnostic specificity. The parallel decrease in C. difficile specific antibiotic use offers indirect reassurance against under-diagnosis of C. difficile infections still requiring treatment by clinician …

Is the Healthcare Facility Level Sufficient for Assessing the Impact of Two-Step Clostridioides difficile Testing?

Implementation of a standardized order set, focused on pre-defined quality indicators for hospitalized patients with severe UC, was associated with meaningful improvements to most quality indicators defined by the Toronto Consensus Statements.